Article
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
BMJ (Clinical research ed.) - 23 Sept 2015
Ko Tai-Ming, Tsai Chang-Youh, Chen Shih-Yang, Chen Kuo-Shu, Yu Kuang-Hui, Chu Chih-Sheng, Huang Chung-Ming, Wang Chrong-Reen, Weng Chia-Tse, Yu Chia-Li, Hsieh Song-Chou, Tsai Jer-Chia, Lai Wen-Ter, Tsai Wen-Chan, Yin Guang-Dar, Ou Tsan-Teng, Cheng Kai-Hung, Yen Jeng-Hsien, Liou Teh-Ling, Lin Tsung-Hsien, Chen Der-Yuan, Hsiao Pi-Jung, Weng Meng-Yu, Chen Yi-Ming, Chen Chen-Hung, Liu Ming-Fei, Yen Hsueh-Wei, Lee Jia-Jung, Kuo Mei-Chuan, Wu Chen-Ching, Hung Shih-Yuan, Luo Shue-Fen, Yang Ya-Hui, Chuang Hui-Ping, Chou Yi-Chun, Liao Hung-Ting, Wang Chia-Wen, Huang Chun-Lin, Chang Chia-Shuo, Lee Ming-Ta Michael, Chen Pei, Wong Chih-Shung, Chen Chien-Hsiun, Wu Jer-Yuarn, Chen Yuan-Tsong, Shen Chen-Yang
Abstract excerpt
OBJECTIVE: To evaluate the use of prospective screening for the HLA-B*58:01 allele to identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) induced by allopurinol treatment. DESIGN: National prospective cohort study. SETTING: 15 medical centres in different regions of Taiwan, from July 2009 to August 2014. PARTICIPANTS: 2926 people who had an indication for allopurinol treatment but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.